Crossmark

MIM1 – a selective Mcl-1 protein inhibitor augments the proapoptotic activity of moxifloxacin toward MDA-MB-231 triple-negative breast cancer cells – a preliminary in vitro study

Crossref DOI link: https://doi.org/10.1007/s43440-025-00780-z

Published Online: 2025-09-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beberok, Artur https://orcid.org/0000-0003-2247-3004
Rzepka, Zuzanna

Rok, Jakub

Karkoszka-Stanowska, Marta

Wrześniok, Dorota
Funding

Funding for this research was provided by:

Medical University of Silesia in Katowice (BNW-1-037/N/4/F and BNW-1-035/K/5/F)
License Information

Text and Data Mining valid from 2025-09-02

Version of Record valid from 2025-09-02
More Information

Article History

Received: 9 September 2024

Revised: 25 August 2025

Accepted: 26 August 2025

First Online: 2 September 2025

Declarations

:

: Not applicable.

: All authors have provided their consent to the publication of this manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below